Cargando…
New Oral Anticoagulants Open New Horizons for Cancer Patients with Venous Thromboembolism
Venous thromboembolism (VTE) is associated with increased morbidity and mortality, decreased quality of life, and higher economic burden in patients with cancer. Currently, the treatment of VTE in patients with cancer is particularly challenging. For many years, low molecular weight heparin (LMWHs)...
Autores principales: | Wumaier, Kaidireyahan, Li, Wenqian, Cui, Jiuwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357558/ https://www.ncbi.nlm.nih.gov/pubmed/35959418 http://dx.doi.org/10.2147/DDDT.S373726 |
Ejemplares similares
-
Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis
por: Wumaier, Kaidireyahan, et al.
Publicado: (2021) -
New anticoagulants for the prevention of venous thromboembolism
por: Becattini, Cecilia, et al.
Publicado: (2010) -
New anticoagulants for the treatment of venous thromboembolism
por: Fernandes, Caio Julio Cesar dos Santos, et al.
Publicado: (2016) -
New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients
por: Gerotziafas, Grigoris T, et al.
Publicado: (2014) -
New horizons in anticoagulation: Direct oral
anticoagulants and their implications in oral surgery
por: Serrano-Sánchez, Víctor, et al.
Publicado: (2017)